June 24th 2024
While plenty of studies have been done looking at how blood cells function within bone marrow, new research looks deeper at other cells, and resulted in the collaborators creating a Bone Marrow Atlas.
Breyzani Approved For CLL/SLL and FDA Advisory Committee Votes in Favor of Abecma for MM
March 21st 2024Last week, BMS announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has voted in favor of BMS’s and 2seventy bio's Abecma (idecabtagene vicleucel) for patients with relapsed or refractory multiple myeloma in earlier lines of therapy.
Read More
The trial evaluated Adcetris in combination with Revlimid and Rituxan compared to Revlimid and Rituxan plus placebo in adult patients with relapsed/refractory DLBCL who have received two or more prior lines of therapy and are ineligible for stem cell transplant or CAR-T therapy.
Read More
New Study Suggests Effective Management Strategies for High Blood Pressure with Imbruvica
February 13th 2024Imbruvica is an oral medication prescribed to treat certain B-cell malignancies, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenstrom macroglobulinemia.
Read More
New Study Shows Racial Disparities in Treatment and Survival Among Seniors with Multiple Myeloma
February 7th 2024The development of new and improved therapeutic agents has improved the treatment outcomes for MM over the past few decades. It remains unclear whether these racial disparities have persisted in the era of novel agents.
Read More
Obesity, Heavy Smoking and Short Sleep Linked to Increased Risk of Multiple Myeloma
January 18th 2024Those who suffer from obesity, heavy smoking and short sleep have a higher chance of developing mass spectrometry (MS) and monoclonal gammopathy of undetermined significance (MGUS), which can often lead to multiple myeloma.
Read More
Leukemia Death, Survival Trends Are Improving in the Era of Targeted Treatment
January 18th 2024The outlook for leukemia patients improved after Gleevec (imatinib) was approved in 2001 as a treatment for chronic myeloid leukemia. The American Cancer Society published its annual cancer statistics report today that projects 62,770 new cases of leukemia will be diagnosed this year and 23,670 deaths from the disease will occur.
Read More
For Multiple Myeloma Patients, Convenience Now an Important Factor in the Treatment Equation
December 20th 2022The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).
Read More
Bispecific Antibody Treatments for Multiple Myeloma Are on Their Way
November 15th 2022Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.
Read More
Young Adult Black Patients With Acute Myeloid Leukemia Patients Have Higher Death Rate
November 15th 2022The younger Black patients with acute myeloid leukemia (AML) had “alarmingly high” early death rates within the first 30 days of study enrollment, indicating possible delays in diagnosis and care, according to research results reported in the journal Blood Advances.
Read More
Adcetris, an Antibody-Drug Conjugate, Shows Promise As a Treatment for Pediatric Hodgkin Lymphoma
November 14th 2022Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.
Read More
The FDA approved Tecvayli (teclistamab) yesterday after approving two CAR-T therapies as late-line treatments for multiple myeloma earlier this year. Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.
Read More